News
[CLOSED] Public consultation of the Draft Project Plan on “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”
We are pleased to announce that as of today the Draft Project Plan “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”, produced within
HTA Core Model Version 3.0 draft – comments welcome!
Continuous improvement of the HTA Core Model – Version 3.0 has been made available as a public draft. Continuous improvement of the HTA Core Model
WP7 SG2 Position paper on how to decide on the appropriate study design for AEG available
WP7 Subgroup 2 is pleased to announce the publication of the Position paper on how to decide on the appropriate study design for primary research
The summary of the EUnetHTA-EMA face-to-face meeting on 8 May, 2015, is available
Meeting minutes from the EUnetHTA-EMA meeting that took place 8 May 2015 in London, UK, is now available. Find the minutes here. Find all minutes from
[CLOSED] Public consultation of Draft Project Plan of the sixth pilot of WP5 Strand A: Rapid Relative Effectiveness Assessment of new pharmaceuticals for the treatment of chronic hepatitis C
We are pleased to announce that as of today the Draft Project Plan regarding the production of a Rapid Relative Effectiveness Assessment of new pharmaceuticals
[CLOSED] Public consultation on “the use of Intravenous immunoglobulins for Alzheimer’s disease including Mild Cognitive Impairment”
We are happy to announce that the second Core HTA produced within the EUnetHTA Joint Action 2 Work Package 4 is available for public feedback.
The Joint Assessment on “Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)” is now available
The Joint Assessment on “Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)” is now available
EUnetHTA partners’ Annual Reports 2014
We are starting to provide links to the EUnetHTA partners’ Annual Reports. The links could be found via the individual profiles of the partner organisations
The 4th pilot rapid assessment of WP5 JA2 Strand B on “Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenosis” is now available
We are pleased to announce that the 4th pilot rapid assessment of WP5 JA2 Strand B on “Biodegradable stents for the treatment of refractory or
[CLOSED] Public consultation on the position paper on how to decide on the appropriate study design for primary research arising from HTA
In order to gather as much feedback as possible, WP7 Subgroup 2 has decided to extend the public consultation period on the Position paper on
